Key result
Optimizing statin and antiplatelet therapy addresses persistent sex-based treatment disparities in high-risk cardiovascular disease.
Why the study?
Cardiovascular disease remains the leading cause of morbidity and mortality among women globally, with persistent sex-based differences in treatment and outcomes.
Answers are grounded in this paper and cite their sources.
This paper reviews strategies to overcome sex-based differences in the use of statin and antiplatelet therapies for women with high-risk cardiovascular disease.
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality among women globally, accounting for approximately one-third of all deaths [1–3]. Despite decades of research, a...
No takes yet. Share an insight, caveat, or question.
Garcia-Zamora et al. (2026) studied this question. Targeted statin and antiplatelet therapy must be optimized to overcome persistent sex-based disparities in the management of women with high-risk cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: